News & Updates

New drug applications approved by US FDA as of 16-28 February 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Promoting healthy habits through a behaviour-based lifestyle program helps keep metabolic syndrome (MetS) in remission after treatment, according to the Enhancing Lifestyles in Metabolic Syndrome (ELM) study.

Vitamin concentrations indicative of adequate nutrient intake appear to have a potential role in metabolic regulation and mental wellbeing in Asian women, according to local research.

Remission of prediabetes has been found to substantially lower the risk of cardiovascular morbidity and mortality in a study, and this cardiovascular protection persists for decades.

A recent study has shown the comparable effectiveness of fixed (fCPAP) and auto-titrating continuous positive airway pressure (APAP), with some outcomes favouring fCPAP, in patients with obesity hypoventilation syndrome (OHS) and severe obstructive sleep apnoea (sOSA).

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in patients with diabetes or heart diseases is not associated with increased risk of optic nerve or vision-threatening events, and plays a role in improving the long-term success rate of curative catheter ablation for atrial fibrillation (AF) in cardiac patients with obesity, researchers from the University of Hong Kong (HKU) have found.

Diagnosis of growth hormone deficiency (GHD) is important and should be made early as it is easily treatable with GH replacement (somatropin) therapy. In an interview with MIMS Doctor, Dr Wai-Man But gave an overview of the diagnosis and management of GHD, and shared a patient case who achieved growth normalization with early initiation of GH treatment.

Treatment with a glucagon-like peptide-1 receptor agonist (GLP-1RA) in combination with adherence to healthy lifestyle habits yields a greater reduction in the risk of cardiac events in individuals with type 2 diabetes (T2D) compared with GLP-1RA treatment alone, according to a prospective study.